Orthopediatrics CORP: management transactions · United States · SEC (Form 4)

About Orthopediatrics CORP

OrthoPediatrics Corp. (ticker: KIDS) is a United States-based medical device company listed on the Nasdaq. Founded in 2006 and headquartered in Warsaw, Indiana, the company is a pure-play pediatric orthopedics platform built around a single, highly specialized therapeutic area: musculoskeletal care for children. For European investors, the appeal lies in its niche positioning, its differentiated product development model, and its exposure to a long-duration healthcare theme centered on pediatric surgical innovation. The company develops and commercializes implant and instrument systems designed specifically for pediatric patients. Its core business lines include trauma and deformity correction, scoliosis, sports medicine, and adjacent pediatric orthopedic procedures. Over time, OrthoPediatrics has broadened its platform beyond classic surgical hardware by adding specialty bracing and other non-operative solutions, reflecting a strategy to serve patients across the full treatment continuum. That expansion has been supported by targeted acquisitions and by the launch of dedicated divisions aimed at widening the company’s addressable market. From a competitive standpoint, OrthoPediatrics is differentiated by focus. Unlike large diversified orthopedic manufacturers, it concentrates exclusively on pediatric orthopedics, which allows it to design products around the anatomical and clinical requirements of growing children. This specialization can create a meaningful advantage in physician relationships, clinical adoption, and product relevance, especially in complex cases where adult-oriented systems are less suitable. The company also promotes itself as offering one of the broadest pediatric orthopedic portfolios in the market. Geographically, the United States remains the company’s primary market, but international sales are an increasingly important part of the growth profile. Recent operating updates point to continued momentum. In the first quarter of 2026, OrthoPediatrics reported revenue of $59.4 million, up 13% year over year, with both domestic and international growth and improved adjusted EBITDA. In January 2026, management announced preliminary full-year 2025 revenue of $236.1 million, a record level, and introduced 2026 guidance. The company also highlighted record numbers of children helped, reinforcing the scale of its clinical footprint and the commercial traction of its franchise. Recent strategic developments have also been noteworthy. The specialty bracing division has continued to expand into additional territories and clinic locations, strengthening the company’s non-surgical offering and extending its commercial reach. Taken together, these developments suggest a company that is still in expansion mode, combining product innovation, market-share gains, and broader clinical coverage. For investors analyzing U.S.-listed healthcare names, OrthoPediatrics is a focused growth story on the Nasdaq in the United States, with a defensible niche and a clear specialization advantage.